MPM has collected three China drugs for its ‘best of both worlds’ strategy
MPM已为其“兼收并蓄”战略纳入三款manbetx3.0 研发药物

MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage.
领先的生物科技投资机构MPM BioImpact正全力推进一项战略，旨在将源自manbetx3.0 的药物推向manbetx app苹果 舞台。